FAPI-guided surgery for newly diagnosed medullary thyroid cancer
Part of Cancer clinical trials.
This trial tests whether a special imaging agent (FAPI) can help surgeons remove medullary thyroid cancer more precisely during your first surgery. It is for people who have not yet been treated and are scheduled for surgery within 30 days.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with medullary thyroid cancer that has not spread to distant parts of the body.
- Your cancer has not been treated before (no prior surgery, radiation, targeted therapy, or other treatments).
- You are healthy enough for surgery (your blood cell counts, liver, and kidney function are within normal limits).
- Your doctor plans to perform surgery within the next 30 days.
- You are not pregnant, not planning pregnancy, and willing to use effective birth control during the study and for 6 months after.
- You have no other cancers, no severe claustrophobia, no contrast allergy, and can lie still for 30 minutes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging agent (68Ga-DOTA-CCK-FS) that helps doctors see medullary thyroid carcinoma (MTC) and other tumors with CCK-2 receptors using a PET/CT scan. It may help find or monitor these tumors more clearly.
This trial uses a special PET scan to help guide surgery for medullary thyroid cancer (MTC). The goal is to see if this scan can make surgery more precise.
This trial tests a new radioactive treatment (177Lu-CTR-FAPI) that targets a protein on thyroid cancer cells. It's for people whose thyroid cancer has stopped responding to standard treatments, including radioactive iodine and targeted therapies.
This trial looks at whether a special PET scan can find metastatic tumors and guide a targeted radiation treatment. It may help people by improving how doctors locate tumors and decide where to deliver therapy.
This trial tests whether removing half the thyroid with nearby lymph nodes is effective for medullary thyroid cancer. Medullary thyroid cancer is a rare type that starts in cells producing calcitonin, a hormone that controls calcium levels.
This trial tests a special PET scan (68Ga-FAPI) to see if it can better find thyroid cancer that has come back or spread after surgery. It may help your doctor decide on the best next steps for your care.
Hear when a new Medullary Thyroid Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.